RecruitingRecruiting
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
NCT06589830 · Teligene US
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2 Study to Evaluate TL938 Combined With Trastuzumab in Patients With HER2-Positive Advanced Colorectal Cancer
About this study
This Phase 2 study evaluates TL938 alone or in combination with trastuzumab in patients with HER2-positive advanced colorectal cancer. Cohort 1 determines the recommended Phase 2 dose of TL938 with trastuzumab. Cohorts 2 and 3 evaluate the efficacy and safety of TL938 with trastuzumab or TL938 alone at that dose.
Eligibility criteria
Inclusion Criteria:
1. Age 18 years or older.
2. Histologically or cytologically confirmed metastatic and/or unresectable adenocarcinoma of the colon or rectum.
3. HER2-positive (IHC 3+ or HER2 gene amplification) and RAS wild-type tumor.
4. Disease progression after at least 2 prior lines of standard systemic therapy, unless contraindicated.
5. At least one measurable lesion per RECIST 1.1.
6. ECOG performance status 0 to 2.
7. Adequate bone marrow, liver, kidney, and coagulation function.
8. Other inclusion criteria apply.
Exclusion Criteria:
1. Prior anti-HER2 targeted therapy (prior antibody-drug conjugates allowed in Cohort 1).
2. Symptomatic or uncontrolled central nervous system metastases.
3. Another primary malignancy within 3 years, except adequately treated low-risk cancers.
4. Uncontrolled active infection.
5. Clinically significant cardiovascular disease.
6. Pregnant or breastfeeding.
7. Other exclusion criteria apply.
Study design
Enrollment target: 110 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-05-13
Estimated completion: 2029-12
Last updated: 2026-11-12
Interventions
Drug: TL938 CapsulesDrug: Trastuzumab
Primary outcomes
- • Dose limiting toxicity, maximum tolerated dose, and recommended phase 2 dose (Pre-dose up to approximately 24 months post-dose)
- • Objective Response Rate (ORR) by IRC (Pre-dose up to approximately 24 months post-dose)
Sponsor
Teligene US · industry
With: Suzhou Teligene Ltd.
Contacts & investigators
ContactXiaoyang Xia, Ph.D. · contact · Xiaoyang.xia@teligene.com · 8053009373
ContactDawei Zhang, Ph.D. · contact · david.zhang@teligene.com · 8053001019
All locations (1)
Cancer Hospital, Chinese Academy of Medical SciencesRecruiting
Beijing, Beijing Municipality, China